Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2019-07-03 Major Shareholding Noti…
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in Episurf Medical AB. It explicitly mentions 'Reason for major shareholding notification' and provides 'Before the transaction' and 'After the transaction' figures, including the new percentage (4.58%) and share count (4,249,638). This structure perfectly matches the definition of a Major Shareholding Notification. The filing type code corresponding to this is MRQ.
2019-07-03 English
Ytterligare kanadensiskt patentbeviljande för Episurf Medical
Regulatory Filings Classification · 1% confidence The document is a short press release written in Swedish announcing that the Canadian Patent Office (CIPO) intends to grant an additional patent to Episurf Medical. It details the patent's scope (method and node for manufacturing a surgical kit for cartilage repair) and includes quotes, contact information, and a boilerplate 'About' section. Crucially, the final paragraph states: "Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is information that Episurf Medical AB is obliged to disclose pursuant to the EU Market Abuse Regulation). This structure—a brief announcement of a specific corporate event (patent grant) mandated by market regulations—fits best under the general regulatory announcement category, as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a non-standard, mandatory regulatory disclosure that doesn't fit a more specific category like DIRS, DIV, or CAP. The document length (1806 chars) also suggests it is an announcement rather than a comprehensive report.
2019-07-03 Swedish
Episurf Medical announces that trading with paid-up shares will end on 1 July 2019
Share Issue/Capital Change Classification · 1% confidence The document is a short announcement from Episurf Medical regarding the conclusion of trading for shares issued during a rights issue and the registration of new shares. Key phrases include 'rights issue that raised SEK 75.2m', 'Trading in paid-up shares created in Episurf Medical AB's (publ) rights issue in May 2019 will end', and '478,147 new shares... have been registered'. This directly relates to changes in the company's capital structure and financing activities. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it is a specific announcement about capital structure changes resulting from a financing event, CAP is the most precise fit.
2019-06-28 English
Episurf Medical meddelar att handel med BTA avslutas den 1 juli 2019
Share Issue/Capital Change Classification · 1% confidence The document announces the conclusion of trading for temporary shares (BTA) issued during a rights issue ('förtresemission') and the registration of new A and B shares. This directly relates to changes in the company's capital structure and financing activities. The key phrases are 'förtresemission', 'handel med BTA avslutas', and the registration of new shares. This aligns best with the 'Capital/Financing Update' category.
2019-06-28 Swedish
Klart för rekrytering av Episealer®-patienter i USA
Regulatory Filings Classification · 1% confidence The document is a short announcement from Episurf Medical regarding a clinical study ('EPIC-Knee Episealer® Knee System IDE Clinical Study') being ready to recruit patients in the USA. It details the progress of the IDE study, which is a step towards PMA approval. The text concludes with a statement that this information is required to be made public under the EU Market Abuse Regulation and specifies the release time and date (June 26, 2019). This format—a brief update on a specific corporate/regulatory event (clinical trial progress towards US approval) released via an official channel—is characteristic of a general regulatory announcement or press release that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Since it is not a full report, and it is a specific regulatory update, the most appropriate general category is Regulatory Filings (RNS), as it serves as a catch-all for official, non-standardized announcements.
2019-06-26 Swedish
Ready for enrolment of Episealer® patients in the US
Regulatory Filings Classification · 1% confidence The document announces a specific operational update regarding a clinical study (EPIC-Knee Episealer® Knee System IDE Clinical Study) readiness for patient enrolment in the US. It details progress, next steps toward US market approval (PMA route), and includes quotes from the CEO and COO. This type of announcement, which is a specific operational or strategic update that doesn't fit neatly into standard financial reports (10-K, ER, IR) or governance filings (DEF 14A, DVA), is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update if the IDE study itself is considered a regulatory hurdle. Given the context of a specific, non-financial operational milestone announcement, and lacking keywords for specific financial reports, RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fallback category. The document length is short (2896 chars), suggesting it is an announcement rather than a full report.
2019-06-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.